Genetic biomarkers for hepatocellular cancer risk in a caucasian population

Table 3 Odds ratios and corresponding 95%CI for hepatocellular carcinoma compared to hepatitis B/hepatitis C infected patients and blood donors according to genetic polymorphisms

Gene	SNP	Allelic change	HCC vs HBV/HCV			HCC vs Healthy
			Mod	OR (95%CI)1	P value	Mod	OR (95%CI)2	P value
ERCC1	rs3212986	G>T	Dom	0.46 (0.30-0.71)	0.0005b	Dom	0.43 (0.28-0.65)	< 0.0001b
XRCC3	rs1799794	A>G	Rec	3.70 (1.02-13.39)	0.0461a	Rec	2.44 (0.84-7.08)	0.1003
GST-P1	rs1138272	C>T	Dom	0.41 (0.21-0.81)	0.0097b	Add	1.58 (0.70-3.57)	0.2699
CYP17A1	rs743572	T>C	Dom	0.50 (0.31-0.79)	0.0032b	Add	0.73 (0.55-0.97)	0.0310a
ABCB1	rs1128503	C>T	Rec	2.06 (1.18-3.61)	0.0111a	Dom	1.22 (0.75-1.98)	0.4194

¹Estimated through logistic regression model, adjusted for sex, age and HBV and/or HCV infection;

²Estimated through logistic regression model, adjusted for sex and age.

^aP < 0.05,

^bP< 0.01. HCC: Hepatocellular carcinoma; SNP: Single-nucleotide polymorphism; HBV: Hepatitis B viral; HCV: Hepatitis C viral.